Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nalmefene
Drug ID BADD_D01522
Description Nalmefene is a 6-methylene analogue of naltrexone and opioid system modulator but with no opioid activity [FDA Label]. It mediates a partial agonist effect on kappa receptors [A31301]. It is primarily used in the management of alcohol dependence in adult patients in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption [L1024] when it is exists as the hydrochloride dihydrate form under the trade name Selincro. Selincro is orally administered as tablets. Nalmefene works to reduce alcohol consumption in individuals by positive reward effect of alcohol which involves the opioid system, as well as the sedative and dysphoric properties of alcohol [A31301]. It is also indicated to prevent or reverse the effects of opioids, including respiratory depression, sedation, and hypotension by acting on the opioid receptor as an antagonist [FDA Label] under the trade name Revex for intramuscular, intravenous and subcutaneous injection, where nalmefene hydrochloride is an active ingredient.
Indications and Usage Indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification [L1024]. Indicated for the complete or partial reversal of opioid drug effects, including respiratory depression - induced by either natural or synthetic opioids - or in the management of known or suspected opioid overdose [FDA Label].
Marketing Status approved; investigational; withdrawn
ATC Code N07BB05
DrugBank ID DB06230
KEGG ID D05111
MeSH ID C038981
PubChem ID 5284594
TTD Drug ID D05VIL
NDC Product Code 82712-1002
UNII TOV02TDP9I
Synonyms nalmefene | Revex | Selincro | 6-desoxy-6-methylenenaltrexone | nalmefene hydrochloride
Chemical Information
Molecular Formula C21H25NO3
CAS Registry Number 55096-26-9
SMILES C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation19.06.02.001; 17.02.05.012--
Alcoholic psychosis19.03.01.005; 12.03.01.047--Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dissociation19.14.01.002--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Dry mouth07.06.01.002--
Dysphoria19.04.02.004--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Hallucination19.10.04.003--
Hallucination, auditory19.10.04.004--Not Available
Hallucination, visual19.10.04.007--Not Available
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023; 23.03.03.081--Not Available
Hypotension24.06.03.002--
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene